文献速递组学、生物样本库与精准医学医学人工智能与信息学基础与转化研究

未受抗生素破坏的肠道微生物组与CD19-CAR-T细胞癌症免疫治疗的临床反应相关

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
PubMed 文献 · Nat Med · 2023-03-13

在德国和美国五个中心的B细胞淋巴瘤患者队列中(德国n=66,美国n=106,总计n=172),广谱抗生素治疗与CD19-CAR-T细胞治疗不良结局相关,但该效应可能受治疗前肿瘤负荷和全身性炎症混杂。在未暴露于高风险抗生素的患者中,CAR-T输注前长双歧杆菌和微生物编码的肽聚糖生物合成与6个月生存或淋巴瘤进展显著相关,基于微生物组的机器学习算法可区分长期应答者与非应答者。

要点

  • CD19-CAR-T治疗前使用高风险抗生素与不良结局相关,但可能受肿瘤负荷和炎症混杂。
  • 未暴露高风险抗生素患者中,长双歧杆菌和肽聚糖生物合成与6个月生存或进展显著相关。
  • 基于微生物组的机器学习算法在德国队列训练并在美国队列验证,可区分长期应答者。

核心结论

  • 未受抗生素破坏的肠道微生物组特征与CD19-CAR-T细胞治疗的临床反应相关,并可能实现跨队列的基于微生物组的结局预测。

研究设计与样本

  • 来自德国和美国五个中心的B细胞淋巴瘤患者队列(德国n=66,美国n=106,总计n=172)。

主要发现

  • CD19-CAR-T治疗前使用广谱抗生素(高风险抗生素)与不良结局相关,但该效应可能受治疗前肿瘤负荷增加和全身性炎症混杂。
  • 在未暴露于高风险抗生素的患者中,CAR-T输注前长双歧杆菌和微生物编码的肽聚糖生物合成与CAR-T治疗相关的6个月生存或淋巴瘤进展显著相关。
  • 在未暴露于高风险抗生素的德国队列中训练的基于治疗前微生物组的机器学习算法,经美国队列验证,可稳健区分长期应答者与非应答者。
  • Bacteroides、Ruminococcus、Eubacterium和Akkermansia在决定CAR-T反应性中最为重要,其中Akkermansia还与这些患者输注前外周T细胞水平相关。

关键数值与推荐

  • 德国队列n=66,美国队列n=106,总计n=172。
  • 在未暴露于高风险抗生素的患者中,CAR-T输注前长双歧杆菌和微生物编码的肽聚糖生物合成与6个月生存或淋巴瘤进展显著相关。
  • 基于微生物组的机器学习算法在德国队列训练、美国队列验证,可稳健区分长期应答者与非应答者。
  • Bacteroides、Ruminococcus、Eubacterium和Akkermansia在决定CAR-T反应性中最为重要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States (Germany, n = 66; United States, n = 106; total, n = 172), we demonstrate that wide-spectrum antibiotics treatment ('high-risk antibiotics') prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with high-risk antibiotics. To resolve this confounding effect and gain insights into antibiotics-masked microbiome signals impacting CAR-T efficacy, we focused on the high-risk antibiotics non-exposed patient population. Indeed, in these patients, significant correlations were noted between pre-CAR-T infusion Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis, and CAR-T treatment-associated 6-month survival or lymphoma progression. Furthermore, predictive pre-CAR-T treatment microbiome-based machine learning algorithms trained on the high-risk antibiotics non-exposed German cohort and validated by the respective US cohort robustly segregated long-term responders from non-responders. Bacteroides, Ruminococcus, Eubacterium and Akkermansia were most important in determining CAR-T responsiveness, with Akkermansia also being associated with pre-infusion peripheral T cell levels in these patients. Collectively, we identify conserved microbiome features across clinical and geographical variations, which may enable cross-cohort microbiome-based predictions of outcomes in CAR-T cell immunotherapy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Stein-Thoeringer CK, Saini NY, Zamir E, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023. PMID: 36914893. doi:10.1038/s41591-023-02234-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。